| 摘要 |
PURPOSE:The titled pharmaceutical, obtained by forming propranolol which is a beta-blocker as an enteric dosage form, capable of enhancing the migration from the stomach to duodenum and keeping the concentration in the duodenum at a remedially effective amount and efficiently treating angina pectoris, arrhythmia, etc. CONSTITUTION:A propranolol pharmaceutical obtained by enteric coating of propranolol [chemical name; 1-isopropylamino-3-(1-napththyloxy)-2-propanol] with an enteric film material, preferably cellulose acetate phthalate and administered as an enteric dosage form. The dosage form is normally tablet, but may be granule or capsule. The case of low absorption ratio in conventional oral administration is not decomposition by gastric acid or metabolism by enterobacteria but caused by slow migration rate from the stomach to the duodenum. The enteric dosage form enhances the blood concentration in the duodenum which is an absorption site and improves the drug effect.
|
